Verastem, Inc. (NASDAQ:VSTM) recently announced that the FDA has accepted their NDA for accelerated approval for the combination of avutometinib and defactinib “recurrent low-grade serous ... More @Wikipedia
Hover over any link to get a description of the article. Please note that search keywords are sometimes hidden within the full article and don't appear in the description or title.